Table III.
Serum levels of HA, LN, IV-C and PCIII in rats.
| Measurement | Control | Model | Colchicine | Cilostazol (5 mg/kg) | Cilostazol (10 mg/kg) | Cilostazol (20 mg/kg) | Cilostazol-only (10 mg/kg) |
|---|---|---|---|---|---|---|---|
| HA | 201.6±32.3 | 451.3±34.5a | 233.4±36.1b | 457.8±39.1 | 286.4±32.2b | 259.3±28.7b | 195.6±23.4 |
| LN | 33.1±2.8 | 56.9±3.8a | 38.9±4.1b | 58.7±4.5 | 44.6±5.1b | 40.5±3.4b | 32.6±3.1 |
| IV-C | 18.4±3.1 | 39.1±3.5a | 21.3±2.7b | 38.7±3.4 | 25.2±4.4b | 23.3±3.7b | 17.9±2.6 |
| PCIII | 47.6±10.3 | 210.7±32.4a | 103.8±10.9b | 203.9±24.5 | 169.8±13.6b | 150.6±16.8b | 45.8±9.5 |
Control, rats received no treatment; Model, rats received oral alcohol infusions to induce liver fibrosis; Colchicine, rats received oral alcohol and colchicine (0.1 mg/kg/day); Cilostazol (5, 10 or 20 mg/kg), rats received oral alcohol and cilostazol at 5, 10 or 20 mg/kg/day; Cilostazol-only (10 mg/kg), rats received oral cilostazol at 10 mg/kg/day. Data are presented in ng/ml and as the mean ± standard deviation (n=20/group).
a
P<0.05 vs. Control
b
P<0.05 vs. Model. HA, hyaluronic acid; LN, laminin; IV-C, type IV collagen; PCIII, type III precollagen.